Aspirin Use and Respiratory Morbidity in COPD

Fawzy, Ashraf; Putcha, Nirupama; Aaron, Carrie P.; Bowler, Russell P.; Comellas, Alejandro P.; Cooper, Christopher B.; Dransfield, Mark T.; Han, MeiLan K.; Hoffman, Eric A.; Kanner, Richard E.; Krishnan, Jerry A.; Labaki, Wassim W.; Paine, Robert; Barr, R. Graham; Hansel, Nadia N.; Alexis, Neil E.; Anderson, Wayne H.; Barjaktarević, Igor; Bleecker, Eugene R.; Boucher, Richard C.; Carretta, Elizabeth E.; Christenson, Stephanie A.; Couper, David J.; Criner, Gerard J.; Crystal, Ronald G.; Curtis, Jeffrey L.; Doerschuk, Claire M.; Freeman, Christine M.; Hastie, Annette T.; Kaner, Robert J.; Kleerup, Eric C.; LaVange, Lisa M.; Lazarus, Stephen C.; Martínez, Fernando J.; Meyers, Deborah A.; Moore, Wendy C.; Newell, John D.; Paulin, Laura M.; Peters, Stephen P.; Pirozzi, Cheryl; Oelsner, Elizabeth C.; O’Neal, Wanda K.; Ortega, Victor E.; Raman, Sanjeev; Rennard, Stephen I.; Tashkin, Donald P.; Wells, James M.; Wise, Robert A.; Woodruff, Prescott G.

doi:10.1016/j.chest.2018.11.028

Cited by 28 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…129 Daily use of aspirin is associated with a lower incidence of COPD exacerbations, less dyspnea, and a higher quality of life. 130 However, aspirin plus ticagrelor antiplatelet treatment did not work in about one-third of COPD patients without a history of CVD. 131 Calcium channel blockers.…”

Section: Potential Pulmonary Risks For Patients With Cad When Using D...mentioning

confidence: 99%

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Cazzola

Rogliani

Ora

et al. 2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Chronic airway diseases (CAD), mainly asthma and chronic obstructive pulmonary disease (COPD), are frequently associated with different comorbidities. Among them, cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) pose problems for the simultaneous treatment of CAD and comorbidity. Indeed, there is evidence that some drugs used to treat CAD negatively affect comorbidity, and, conversely, some drugs used to treat comorbidity may aggravate CAD. However, there is also growing evidence of some beneficial effects of CAD drugs on comorbidities and, conversely, of the ability of some of those used to treat comorbidity to reduce the severity of lung disease. In this narrative review, we first describe the potential cardiovascular risks and benefits for patients using drugs to treat CAD and the potential lung risks and benefits for patients using drugs to treat CVD. Then, we illustrate the possible negative and positive effects on T2DM of drugs used to treat CAD and the potential negative and positive impact on CAD of drugs used to treat T2DM. The frequency with which CAD and CVD or T2DM are associated requires not only considering the effect that drugs used for one disease condition may have on the other but also providing an opportunity to develop therapies that simultaneously favorably impact both diseases.

show abstract

Section: Potential Pulmonary Risks For Patients With Cad When Using D...mentioning

confidence: 99%

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Cazzola

Rogliani

Ora

et al. 2023

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“… 26 These agents can also contribute to delaying the progression of emphysema, 27 improving dyspnea and quality of life in patients. 28 Furthermore, angiotensin-converting enzyme inhibitor (ACEI) / angiotensin receptor block (ARB) have also been proposed to display a beneficial effect on the risk of cardiovascular events. These drugs may also potentially delay the progression of emphysema while improving the lung function, 29 , 30 with dual cardiorespiratory protective properties.…”

Section: Copd and Cardiovascular Diseases (Cvd)mentioning

confidence: 99%

Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review

Xiang,

Luo

2024

COPD

View full text Add to dashboard Cite

Most patients with chronic obstructive pulmonary disease (COPD) suffer from at least one additional, clinically relevant chronic disease. To a degree, the high global prevalence and mortality rate of COPD is closely related to its extrapulmonary effects. Moreover, the various of comorbidities of COPD and itself interact with each other, resulting in diverse clinical manifestations and individual differences, and thus further influencing the prognosis as well as healthcare burden of COPD patients. This is closely related to the common risk factors of chronic diseases (aging, smoking, inactivity, etc.). Additionally, some pathophysiological mechanisms caused by COPD, including the systemic inflammatory response, hypoxia, oxidative stress, and others, also have an impact on other systems. But comprehensive management and medical interventions have not yet been established. The clinicians should improve their knowledge and skills in diagnosing as well as treating the comorbidities of COPD, and then aim to develop more individualized, efficient diagnostic and therapeutic strategies for different patients to achieve greater clinical benefits. In this article, we will review the risk factors, mechanisms, and treatment strategies for extrapulmonary comorbidities in chronic obstructive pulmonary disease, including cardiovascular diseases, diabetes, anemia, osteoporosis, emotional disorders, and gastroesophageal reflux disease.

show abstract

“…The authors found a significant reduction in the hazard of all-cause mortality by about 30% (HR: 0.71; 95% CI: 0.60, 0.84) [22]. Fawzy et al, 2018, published study findings from 1698 COPD patients who used aspirin for about one month [23]. The authors found that there was a non-significant reduction in the hazard of dyspnea by about 12% (HR: 0.98; 95% CI: 0.79, 1.21) [23].…”

Section: Main Findings Of Each Studymentioning

confidence: 99%

Clinical Outcomes of Aspirin and Clopidogrel among Patients with Chronic Obstructive Lung Disease: Insights from a Meta-Analysis

Alhawiti,

Ismaeil,

Fouda

et al. 2024

JCM

View full text Add to dashboard Cite

(1) Background: Aspirin and clopidogrel have been found helpful in improving clinical outcomes among patients with chronic obstructive lung disease (COPD). However, the evidence on the efficacy of aspirin and/or clopidogrel on clinical outcomes has not been synthesized and summarized in the prior reviews. Hence, we undertook a meta-analysis of the research studies examining the effect of aspirin and/or clopidogrel on varying clinical outcomes among COPD patients; (2) Methods: Using key search terms, we searched databases, including MEDLINE, CINAHL, Google Scholar, and EMBASE to find observational studies and RCTs. Our search was limited to research written in English. We used a random effect model to calculate the 95% confidence intervals and pooled hazard ratio; (3) Results: We included 12 eligible research studies (33,8008 patients) in the current meta-analysis. Among COPD patients, the hazard of all-cause mortality among users of aspirin or clopidogrel was 17% lower (HR: 0.83; 95% CIs (0.70, 0.97; I2 = 73%, X2: 33.34) compared to non-users of anticoagulants (aspirin or clopidogrel). The hazard of dyspnea among users of aspirin or clopidogrel was 3% lower (HR: 0.97; 95% CIs (0.27, 3.49; I2 = 93%, X2: 42.15) compared to non-users of anticoagulants (aspirin or clopidogrel). There was no statistically significant effect of aspirin on other clinical outcomes such as myocardial infarction (HR: 2.04; 95% CIs (0.02, 257.33) and major bleeding (HR: 1.93; 95% CIs (0.07, 1002.33). The funnel plot and Egger’s regression test did not show any evidence of publication bias; (4) Conclusions: Overall, we found a positive and beneficial effect of aspirin and/or clopidogrel in reducing all-cause mortality among COPD patients. However, there is uncertainty of evidence for other clinical outcomes such as exacerbation of dyspnea, myocardial infarction, and major bleeding. A limited number of studies examining other clinical outcomes warrant conducting more robust epidemiological studies to assess the efficacy and safety of aspirin and clopidogrel on other clinical outcomes among COPD patients.

show abstract

Aspirin Use and Respiratory Morbidity in COPD

Cited by 28 publications

References 44 publications

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences

Extrapulmonary Comorbidities Associated with Chronic Obstructive Pulmonary Disease: A Review

Clinical Outcomes of Aspirin and Clopidogrel among Patients with Chronic Obstructive Lung Disease: Insights from a Meta-Analysis

Contact Info

Product

Resources

About